# MBB6: Special Breast Tumour Tissue Array (Human)


13 cases and 3 markers, include pathological grade, and TNM



# **Description:**

| Product code       | MBB6   |  |  |
|--------------------|--|--|--|
| Cases              | 13   |  |  |
| Row number         | 3  |  |  |
| Column number      | 8  |  |  |
| Core diameter (mm) | 0.6  |  |  |
| Thickness          | 4μm  |  |  |
| Tissue array type  | FFPE   |  |  |
| Species            | Human  |  |  |
| Application        | Immunohistochemistry   |  |  |
|                    | In situ hybridization  |  |  |
|                    | Fluorescent in situ hybridization  |  |  |
|                    | <ul> <li>Terminal deoxynucleotidyl transferase dUTP nickend labelling (TUNEL) analysis</li> <li>In situ polymerase chain reaction (In situ PCR)</li> </ul> |  |  |
| Notes              | <ul><li>Storage Temperature: 4°C</li><li>Shipping temperature: Ambient</li></ul>   |  |  |
|                    |  |  |  |

# TMA map:



# **Patient Information:**

| Position | Age    | Gender | Pathology diagnosis   | TNM        | Grade | Type of tumour |  |
|----------|--------|--------|---|------------|-------|----------------|--|
| A1       | Marker |        |   |            |       |                |  |
| A2       | Marker |        |   |            |       |                |  |
| A3       | Marker |        |   |            |       |                |  |
| A4       |        |        |   |            |       |                |  |
| A5       |        |        |   |            |       |                |  |
| A6       |        |        |   |            |       |                |  |
| A7       |        |        |   |            |       |                |  |
| A8       |        |        |   |            |       |                |  |
| B1       | 51     | F      | Multifocal invasive lobular carcinoma                           | T2 N2a MX  | 2     | Malignant      |  |
| B2       | 51     | F      | Invasive lobular carcinoma with signet ring differentiation     | T2 N1a MX  | 2     |                |  |
| В3       | 70     | F      | Invasive pleomorphic lobular carcinoma                          | T1c        | N/A   | Malignant      |  |
| B4       | 52     | F      | Invasive lobular and ductal carcinoma                           | T2 N0 MX   | 2     | Malignant      |  |
| B5       | 68     | F      | Low grade encysted papillary carcinoma with focal microinvasion | N/A        | N/A   |                |  |
| B6       | 61     | F      | Encysted papillary carcinoma with focal stromal invasion        | T2 N0 MX   | 1     | Malignant      |  |
| B7       | 77     | F      | Invasive ductal carcinoma with prominent papillary component    | T2 N0 MX   | 2     | Malignant      |  |
| B8       | 65     | F      | Invasive ductal carcinoma, solid papillary variant              | T1c N0 MX  | 2     | Malignant      |  |
| C1       | 44     | F      | Invasive ductal carcinoma                                       | T1c N1a MX | 2     | Malignant      |  |
| C2       | 44     | F      | Invasive ductal carcinoma                                       | T1c N1a MX | 2     | Malignant      |  |
| C3       | 73     | F      | Mucinous carcinoma  | N/A        | N/A   | Malignant      |  |
| C4       | 48     | F      | Mucinous carcinoma  | T2 N1a MX  | N/A   | Malignant      |  |
| C5       | 39     | F      | Mucinous carcinoma  | N/A        | N/A   | Malignant      |  |
| C6       |        |        |   |            |       |                |  |
| C7       |        |        |   |            |       |                |  |
| C8       |        |        |   |            |       |                |  |

#### Stage description

The American Joint Committee on Cancer (AJCC) TNM system is the frequently employed breast cancer staging system, and it is based on seven important elements:

- The extent (size) of the tumor (T): How large is the cancer? Has it grown into nearby areas?
- The spread to nearby lymph nodes (N): Has the cancer spread to nearby lymph nodes? If so, how many?
- The spread (metastasis) to distant sites (M): Has the cancer spread to distant organs such as the lungs or liver?
- Grade of the cancer (G): How much do the cancer cells look like normal cells?
  - Estrogen Receptor (ER) status: Does the cancer have the protein called an estrogen receptor?
  - Progesterone Receptor (PR) status: Does the cancer have the protein called a progesterone receptor?
  - HER2 status: Does the cancer make too much of a protein called HER2?

### Tumor (T)

**T1:** Tumour ≤ 20 mm in greatest dimension.

**T1a:** Tumor > 1 mm but  $\le 5$  mm in greatest dimension (round any measurement > 1.0-1.9 mm to 2 mm).

**T1b:** Tumor > 5 mm but ≤ 10 mm in greatest dimension

**T1c:** Tumor > 10 mm but ≤ 20 mm in greatest dimension

**T2:** Tumour > 20 mm but ≤ 50 mm in greatest dimension.

**T3:** Tumour > 50 mm in greatest dimension.

**T4:** Tumor of any size growing into the chest wall or skin. This includes inflammatory breast cancer.

T4a: Extension to chest wall, not including only pectoralis muscle adherence/invasion

**T4b:** Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma.

T4c: Both T4a and T4b.

**T4d:** Inflammatory carcinoma.

### Nodes (N)

**NX:** Nearby lymph nodes cannot be assessed.

**NO:** No regional lymph node metastasis identified histologically.

**N1:** Micrometastases; or metastases in 1-3 axillary lymph nodes and/or in internal mammary nodes; and/or in clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy.

**N1a:** Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm).

**N1b:** Metastases in ipsilateral internal mammary lymph nodes, excluding ITCs, detected by sentinel lymph node biopsy

N1c: Combination of N1a and N1b

**N2:** Metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases.

N2a: Metastases in 4-9 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm).

N2b: Metastases in one or more internal mammary lymph nodes, causing them to become enlarged.

N3: Any of the following:

**N3a:** Metastases in  $\geq$  10 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes.

**N3b:** Metastases in at least one axillary lymph nodes (at least 1 tumor deposit > 2.0 mm) and has enlarged the internal mammary lymph nodes; or metastases in 4 or more axillary lymph nodes (at least 1 tumor deposit > 2.0 mm) and in the internal mammary lymph nodes on sentinel lymph node biopsy.

**N3c:** Cancer has spread to the lymph nodes above the collarbone (supraclavicular nodes) on the same side of the cancer with at least one area of cancer spread greater than 2 mm.

## Metastasis (M)

MO: No clinical or radiographic evidence of distant metastasis.

M1: Any histologically proven metastases in distant organs; or if in non-regional nodes, metastases > 0.2 mm.

Mx: Distant metastasis cannot be assessed.